Epic Sciences Developing CTC-based CDx with Drug Firms | GenomeWeb

NEW YORK (GenomeWeb News) – Epic Sciences, which is developing diagnostics to identify and characterize rare cells, said today it is collaborating with six drug manufacturers to develop companion diagnostic tools.

The San Diego-based company declined to identify its drug manufacturer partners, but Genentech, Pfizer, and Celgene have previously disclosed working relationships with Epic.

A company spokesperson declined to elaborate on the nature of the work being done but said that targeted cancers include breast, lung, prostate, pancreatic, and ovarian cancers.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.